

CURRENT PERSPECTIVES IN HAEMATOLOGICAL MALIGNANCIES

Thursday 22nd November 2018

Doubletree by Hilton, Bristol City Centre, Redcliffe Way BS1 6NJ

Chairs: Dr Stephen Robinson (*Bristol*) and Dr Andrew McMillan (*Nottingham*)

09.30 *Registration*

10.00 **Workshop: AML**

- The new drugs we have available
- The trials
- Patient based discussion

Dr Steve Knapper
University Hospital of Wales

Dr Priyanka Mehta
University Hospital Bristol

11.30 *Coffee*

11.50 Continuous therapy in myeloma - the future
(5 mins Q)

Dr Sally Moore
Royal United Hospitals Bath

12.25 CLL - heading for a cure?
(5 mins Q)

Professor Chris Fegan
Cardiff University

13.00 *Lunch*

14.00 **DEBATES:**

ECHELON 1 : Brentuximab should be used first line
in advanced Hodgkin lymphoma

Chair: Dr Andrew McMillan, *Nottingham*
For: Dr Graham Collins, *Oxford*
Against: Dr Wendy Osborne, *Newcastle*

GALLIUM : Obinutuzumab, not rituximab, should
be used first line for patients with symptomatic
follicular lymphoma

Chair: Dr Stephen Robinson, *Bristol*
For: Dr Wendy Osborne, *Newcastle*
Against: Dr Andrew McMillan, *Nottingham*

15.15 *Coffee*

15.40 High risk and resistant CML: new diagnostic tools
and treatment approaches (5 mins Q)

Dr Hugues de Lavallade
King's College Hospital, London

16.15 Myeloproliferative neoplasms - current thinking
(5 mins Q)

Professor Claire Harrison
Guy's and St Thomas' Hospital, London

17.20 *Close*

REGISTRATION:

STANDARD (until 7 th November)	LATE (from 8 th November)
Consultants: £72 Trainees/Nurses: £60 20 free places available for Trainees/Nurses	£108

Fees inclusive of VAT at 20%

Online registration now open at www.hartleytaylor.co.uk

To check availability for one of the free places or for any further information, please contact
alex@hartleytaylor.co.uk or telephone 01565 621967

This meeting is kindly sponsored by:



The sponsors have had no influence over the content of the agenda or speaker selection